



mailed and e-mailed
10-12-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First named inventor:	Ashley Davis	
Application no.:	09/725,030	
Filed:	11/29/00	Examiner: Lukton, D
Title:	Anti-S-phase tubulin ligands	Art Group: 1653

AMENDMENT AND RESPONSE UNDER 37 C.F.R. # 1.111(a)

Mailed to: Box Amendment, Commissioner for Patents, Washington DC 20231.

Dear Sir / Madam:

In response to Office Actions dated 9/21/01, we are submitting amended Claims for the above reference. The amendments are as follows:

In The Claims

Please delete Claims 1 and 2 and amend claims 3-7.

Claim 3 (Amended): - A tubulin ligand that causes an G1/S-phase arrest mechanism.

Claim 4 (Amended): - In combination with Claim 3, where the tubulin ligand is iodine acetamido benzoyl ethyl acetate.

Claim 5 (Amended): - In combination with Claim 3, where the tubulin ligand is bromine acetamido benzoyl ethyl acetate.

Claim 6 (Amended): - In combination with Claim 3, where the tubulin ligand is a derivative of an halogenated acetamido benzoyl ethyl acetate.

Claim 7 (Amended): - In combination with Claim 3, a compound that may have therapeutic potential in treating diseases such as fungal infections, viral infections, parasitic infections, gout, restenosis, multiple sclerosis, Parkinson's and Alzheimer's diseases.

There is one species election, that is halogenated (iodine) acetamido benzoyl ethyl acetate.

Thank you for your diligence in this matter, please inform David Lukton that you have received these amendments.

Yours sincerely,

Ashley Davis, Cytoskeleton Inc.

RECEIVED
OCT 15 2002
OFFICE OF PETITIONS